Currently the clinical management of breast cancer relies on relatively few
prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2) …

Breast cancer ranks first among female cancer-related deaths in Western countries. As the
primary tumor can often be controlled by surgical resection, the survival of women with …

Breast cancer management has witnessed significant advancements, especially in the
diagnosis and treatment response monitoring through the implementation of imaging …

Simple Summary As breast cancer diagnoses continue to rise among women worldwide, it is
important to explore and improve upon methods of diagnosis and surveillance. Liquid …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

Liquid biopsies allow for the detection of cancer biomarkers such as circulating tumor cells
(CTCs) and circulating tumor DNA (ctDNA). Elevated levels of these biomarkers during …

The use of circulating tumor DNA (ctDNA) in liquid biopsy as a biomarker is becoming the
new paradigm for the screening and surveillance of breast and many other cancers. Liquid …

Background The recent advancement in massively parallel sequencing technologies has
empowered liquid biopsies, in particular circulating tumor DNA (ctDNA) analysis, to be the …

Overview the progress of liquid biopsy using circulating tumor cells (CTCs) and circulating
cell-free tumor DNA (cfDNA) to detect and monitor breast cancer. Based on numerous …

Precision Medicine is becoming the new paradigm in healthcare as it enables better
resources allocation, treatment optimization with a potential side-effects reduction and …